Bhuvaneshwar Vaidya

Bhuvaneshwar Vaidya


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Drug Discovery Today
Verified
Journal Article
Closed access
Pawan Kumar MishraPawan Kumar Mishra
Pawan Kumar Mishra
HMHarshita Mishra
Harshita Mishra
Adam EkielskiAdam Ekielski
Adam Ekielski
STSushama Talegaonkar
Sushama Talegaonkar
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya

1 September 2015 in Drug Discovery Today
Verified
Journal Article
Closed access
HSHarshita Sharma
Harshita Sharma
Pawan Kumar MishraPawan Kumar Mishra
Pawan Kumar Mishra
STSushama Talegaonkar
Sushama Talegaonkar
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya

16 July 2013 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Closed access
KKKrishan Kumar
Krishan Kumar
NDNeha Dhawan
Neha Dhawan
HSHarshita Sharma
Harshita Sharma
SVShubha Vaidya
Shubha Vaidya
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
Mucoadhesive drug delivery systems came into picture in the early 1980s and are one of the most studied novel delivery systems. Several researchers have focused on the investigations of the interfacial phenomena of mucoadhesion with the mucus. Mucoadhesion can be defined as a state in which two components, of which one is of biological origin, are held together for an extended period of time by the help of interfacial forces. A number of polymers have shown characteristics of bioadhesion and have been used in the formulation of various conventional and novel drug delivery systems. Studies demonstrated that these carriers not only increase the local therapeutic activity, but also increase the systemic availability of the drugs by increasing the residence time at the site of application. The current review is an attempt to throw some light on the basics of the mucoadhesion: the mechanism of bioadhesion and the polymers that are used in the design of the bioadhesive delivery system with their properties that affect the bioadhesion.

1 March 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
SNSaeideh Nozohouri
Saeideh Nozohouri
ASAli Ehsan Sifat
Ali Ehsan Sifat
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
TAThomas Abbruscato
Thomas Abbruscato

13 October 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
LKLalit Kumar
Lalit Kumar
SVShivani Verma
Shivani Verma
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
Vivek GuptaVivek Gupta
Vivek Gupta
Various cells of the human physiological system have the capability to release extracellular vesicles (EVs) involved in intercellular transport of proteins and nucleic acids. Exosomes are a subtype of extracellular vesicles having their origin through endocytic pathway. While being involved in intercellular transport of macromolecules, exosomes, due to their presence in several body fluids, can also be utilized as a system to commute RNA molecules and proteins in the body. Recent advances in gene therapy have provided a new outlook in disease therapeutics by modulation of gene expression using oligonucleotide based approach and exosomes have been reported a potential carrier for nucleic acid based therapeutic moieties. In recent years, small interfering RNA (siRNA) has emerged as promising therapeutic alternative for diseases with gene-based pathophysiology, however poor bioavailability limits its therapeutic potential. For effective delivery and enhancement of bioavailability of siRNA, several carriers including dendrimers, liposomes, siRNA conjugates, and siRNA aptamer chimeras, to name a few, have been explored. Exosomes can be considered a promising carrier for effective delivery of siRNA due to their existence in body’s endogenous system and high tolerance. The present review focuses on delivering knowledge about exosomes, siRNA, and capability of exosomes to act as natural carriers for siRNA delivery.

10 September 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TAThamer Albekairi
Thamer Albekairi
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
RPRonak Patel
Ronak Patel
SNSaeideh Nozohouri
Saeideh Nozohouri
HVHeidi Villalba
Heidi Villalba
TAThomas Abbruscato
Thomas Abbruscato
Transporters (expressed) at the blood-brain barrier (BBB) can play an essential role in the treatment of brain injury by transporting neuroprotective substance to the central nervous system. The goal of this study was to understand the role of organic anion transporting polypeptide (OATP1; OATP1A2 in humans and oatp1a4 in rodents) in the transport of a potent opioid receptor agonist, biphalin, across the BBB during ischemic stroke. Brain microvascular endothelial cells (BMECs) that were differentiated from human induced pluripotent stem cells (iPSCs) were used in the present study. The effect of oxygen-glucose deprivation (OGD) and reperfusion on the OATP1 expression, uptake, and transport of biphalin was measured in induced pluripotent stem cells differentiated brain microvascular endothelial cells (iPSC–BMECs) in the presence and absence of an OATP1 substrate, estrone-3-sulfate (E3S). Biphalin brain permeability was quantified while using a highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. It was found that iPSC-BMECs expressed OATP1. In vitro studies showed that biphalin BBB uptake and transport decreased in the presence of an OATP1 specific substrate. It was also observed that OGD and reperfusion modulate the expression and function of OATP1 in BMECs. This study strongly demonstrates that OATP1 contributes to the transport of biphalin across the BBB and increased expression of OATP1 during OGD-reperfusion could provide a novel target for improving ischemic brain drug delivery of biphalin or other potential neurotherapeutics that have affinity to this BBB transporter.